INTRODUCTION
============

Primary adrenal insufficiency (PAI), commonly termed Addison\'s disease, is a severe and potentially life-threatening condition \[[@B1]\]. It is defined as the inability of the adrenal cortex to produce sufficient concentrations of glucocorticoids and/or mineralocorticoids. Traditionally, adrenal tuberculosis was the most common cause of PAI; however, in industrialized countries autoimmune disorders are now the predominant cause (\~90%) \[[@B2]\]. PAI is rare, with a reported prevalence of approximately 100 to 221 cases per million inhabitants in European countries and, particularly high in Scandinavia \[[@B3][@B4][@B5][@B6][@B7]\], and a significantly low incidence in other countries, including Japan \[[@B8]\].

Patients with PAI require glucocorticoid and/or mineralocorticoid replacement therapy. However, long-term glucocorticoid replacement therapy can lead to several complications, including reduced bone mineral density, an increased risk of fractures and metabolic disease, and impaired health-related quality of life \[[@B2][@B9]\]. Registry studies have reported high mortality rates in patients with PAI; moreover, mortality is significantly associated with younger age at diagnosis \[[@B9]\].

Due to the rarity of the condition, there are few studies on PAI in Korean adults, and such studies are limited to case reports \[[@B10][@B11][@B12]\] and a clinical review of a small number of patients \[[@B13]\]. To understand the population-based epidemiology of Korean patients with PAI, a nationwide multicenter study is required. Therefore, we performed the first registry-based nationwide survey to obtain data on the epidemiology, clinical characteristics, treatment strategy, and mortality rate of patients with PAI in Korea.

METHODS
=======

Data collection
---------------

We aimed to identify all patients aged ≥18 years diagnosed with or treated for PAI by endocrinologists in Korea. Of all the secondary and tertiary care institutions in Korea, 30 hospitals participated in the search for data from patients with PAI managed at these institutions between January 2000 and December 2014. The registration process took place between June 2015 and February 2016. Patients with PAI were identified based on the following International Classification of Diseases, 10th revision (ICD-10) codes: A18.7 (adrenal tuberculosis), C79.7 (metastatic cancer to the adrenal gland), E27.1--4 and E27.8 (primary adrenocortical insufficiency, adrenal crisis, adrenal gland hypofunction, and other adrenal disease), E31.0 (polyglandular autoimmune syndrome), E37.5 (Addison\'s disease in tuberculosis), and E71.3 (adrenoleukodystrophy). Patients with congenital adrenal hyperplasia, iatrogenic adrenal insufficiency, postoperative adrenal insufficiency, and hypothalamic and/or hypopituitary adrenal dysfunction were excluded.

The medical records of all patients registered in the study were reviewed by multiple endocrinologists to validate the diagnosis of PAI, based on the following criteria: (1) simultaneous plasma levels of adrenocorticotropic hormone (ACTH) above the reference range and of cortisol below the reference range; or (2) a suboptimal response to the corticotropin stimulation test; or (3) clinical symptoms and signs suggestive of PAI, such as hyperpigmentation, typical electrolyte disturbances, salt craving, and chronic treatment with glucocorticoids and/or fludrocortisone.

The following data were collected from the registered patients: age at diagnosis, date of last visit, managing institution, sex, etiology, clinical symptoms, and signs related to adrenal insufficiency, comorbidities, combined autoimmune diseases, results of biochemical tests, glucocorticoid and mineralocorticoid replacement therapy, and mortality. We also collected the patients\' initials, date of birth, and address to exclude duplicated patients.

The study was approved by the Institutional Review Board of each institution participating in the study, based on the same research protocol of Seoul National University Hospital (No. H-1505-051-671), and was conducted in accordance with the Declaration of Helsinki. The need to obtain informed consent from the study participants was waived due to the study\'s retrospective nature.

Statistical analysis
--------------------

The prevalence and annual incidence were calculated based on population census results obtained from the Korean National Statistical Office\'s database. Data are presented as the mean±standard deviation (SD), median and interquartile range (IQR), or number (%) as appropriate. A *P* value of \<0.05 was considered statistically significant. All statistical analyses were performed using SPSS statistics for Windows version 21 (IBM Co., Armonk, NY, USA).

RESULTS
=======

Epidemiology
------------

A total of 269 patients were diagnosed with or treated for PAI between 2000 and 2014. The estimated prevalence of PAI was 4.17 cases per million inhabitants and the estimated incidence was 0.45 cases per million inhabitants per year. [Fig. 1](#F1){ref-type="fig"} shows the observed incidence of PAI over time; no significant change in trend was observed. [Fig. 2](#F2){ref-type="fig"} demonstrates the regional distribution of patients according to the location of each hospital where the patients were diagnosed or treated for PAI. There was a marked difference between the numbers of patients in the different regions, with the majority of patients (76.2%) diagnosed with or treated for PAI in institutions located in Seoul.

Demographics of study subjects
------------------------------

During the study period, the number of patients newly diagnosed with PAI was four times higher between 2000 and 2014 than before 2000. The overall mean age at diagnosis was 49.0±19.7 years. However, patients diagnosed with PAI before 2000 were significantly younger than those diagnosed between 2000 and 2014 (30.7±21.0 years vs. 53.4±16.6 years, respectively; *P*\<0.001). PAI was more prevalent in men than in women except for patients aged 70 to 79 years at diagnosis (1.68:1) ([Table 1](#T1){ref-type="table"}, [Supplemental Fig. S1](#S1){ref-type="supplementary-material"}).

Etiology
--------

The cause of PAI was not identified in 34.9% of all patients. The most common cause of PAI among those for whom the etiology was confirmed, was adrenal tuberculosis (25.7%), followed by metastasis to adrenal gland (18.6%), adrenoleukodystrophy (5.6%), adrenal gland lymphoma (3.7%), adrenal hemorrhage (2.6%), POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome (2.6%), polyglandular autoimmune syndrome (2.2%), congenital adrenal hypoplasia (1.9%), familial glucocorticoid deficiency (1.5%), and Allgrove\'s syndrome (0.8%). [Fig. 3](#F3){ref-type="fig"} shows the etiology of PAI according to the year of diagnosis. Before 2000, adrenal tuberculosis was the leading cause of PAI, whereas the frequency of metastasis to adrenal gland was comparable to that of adrenal tuberculosis between 2000 and 2014.

Clinical manifestations
-----------------------

Common symptoms at presentation were generalized weakness (53.5%), fatigue (41.3%), anorexia (36.8%), weight loss (29.7%), nausea (25.7%), and vomiting (21.2%). Abdominal pain (10.4%), arthralgia/myalgia (7.4%), salt craving (6.3%), diarrhea (4.5%), and constipation (3.7%) were also reported in a small number of patients. Electrolyte imbalance (37.2%) was the most common clinical sign at presentation. Hyperpigmentation (31.2%) and anemia (24.2%) were also common, while orthostatic hypotension (16.0%) and hypotension (15.6%) were reported in \<20% of all patients.

Comorbidities at diagnosis and during follow-up
-----------------------------------------------

The prevalence of hypertension, type 2 diabetes mellitus, and osteoporosis increased during the follow-up period, from 12.6%, 11.9%, and 3.0%, respectively, to 21.2%, 19.0%, and 9.3%, respectively (all *P*\<0.05). There was no significant difference in the prevalence of malignancy, arrhythmias, ischemic heart disease, stroke, and heart failure at diagnosis and during the period of follow-up ([Fig. 4](#F4){ref-type="fig"}). The median duration of follow-up was 60.2 months (IQR, 8.0 to 138.1).

Combined autoimmune diseases
----------------------------

Hypothyroidism was the most common autoimmune disease observed in patients with PAI (13.8%). Other autoimmune disorders---including hyperthyroidism, premature ovarian failure, alopecia, autoimmune hepatitis, vitamin B12 deficiency, and type 1 diabetes mellitus---were reported in \<3% of all patients. Vitiligo was not reported.

Biochemical measurements
------------------------

The median plasma ACTH and serum cortisol levels were 202.0 pg/mL (IQR, 41.7 to 1,022.8) and 4.0 µg/dL (IQR, 1.6 to 8.6), respectively. The median plasma renin activity was 5.0 ng/mL/hr (IQR, 1.1 to 14.8) and the median plasma aldosterone concentration was 8.2 ng/dL (IQR, 2.8 to 19.9). The corticotropin stimulation test was performed in 72.5% of all patients; plasma aldosterone concentrations and plasma renin activity were measured in only 48.2% of those patients. The median peak cortisol level was 8.5 µg/dL (IQR, 3.0 to 12.9) and the median peak plasma aldosterone concentration was 11.1 ng/dL (IQR, 4.2 to 42.3).

Replacement therapy
-------------------

Of the 269 patients, 245 (91.1%) received glucocorticoid replacement therapy ([Table 2](#T2){ref-type="table"}). The preferred glucocorticoid replacement regimen was prednisolone (69.4%), given at a median dose of 7.5 mg once daily. Hydrocortisone was only administered to 26.5% of all patients, at a median dose of 20 mg. Dexamethasone and deflazacort were used in 2.0% and 0.8% of patients, respectively. A significantly lower proportion of patients received mineralocorticoid (27.1%) than glucocorticoid (91.1%) therapy. The median dose of fludrocortisone was 0.1 mg daily.

Mortality
---------

During the follow-up period, 32 patients (11.9%) died. The most common cause of death was malignancy (68.8%), followed by infection (9.4%), pulmonary disease (6.3%), gastrointestinal disease (6.3%), and unknown causes (6.3%). PAI disease-specific mortality was reported in only one case (3.1%).

DISCUSSION
==========

The present study is the first nationwide survey of patients with PAI in South Korea. We identified 269 registered adults diagnosed with or treated for PAI between 2000 and 2014. The estimated prevalence of PAI was 4.17 cases per million inhabitants; this is significantly lower than the prevalence reported in Western countries \[[@B7][@B14][@B15][@B16]\]. The estimated annual incidence of 0.45 cases per million inhabitants is approximately 10% of the incidence reported in national surveys conducted in Sweden and Norway \[[@B17][@B18]\]. The reason for the low incidence of PAI in Korea is unclear; however, it seems that certain racial or regional factors may influence the occurrence of the disease, considering that the incidence of PAI in Korea is similar to that reported in Japan (0.15 per million per year) \[[@B8]\].

Although 30 major secondary and tertiary care institutions participated in this survey, there were some regional differences in the participation rate. This could have resulted in underestimation of the actual incidence of PAI in particular regions with low participation rates. The sex distribution of the condition was somewhat different to that of previous reports, in which PAI was more prevalent in women than in men \[[@B8][@B17][@B18]\]. In the present survey, PAI was more frequently observed in men than in women, with an overall female to male ratio of 1:1.68. It is unclear whether the observed male preponderance is a characteristic of Korean PAI patients or a result of selection bias in this registry-based study.

In the present study, the etiology of PAI was not identified in \>30% of cases. A recently published clinical practice guideline recommends using 21-hydroxylase antibody testing in the diagnostic approach to exclude autoimmunity, because in the majority (\~90%) of cases of adult-onset PAI, the cause is an autoimmune disease \[[@B1]\]. This test is not commercially available in Korea; hence, many of the patients with an unknown etiology are presumed to have autoimmune PAI. The prevalence of combined autoimmune disorders was lower in the present study than in previous studies \[[@B3][@B19][@B20][@B21]\]. However, considering the retrospective design of this record-based study, it is possible that the prevalence of accompanying autoimmune disease was underestimated because of missing data. Therefore, to identify the exact etiologic pattern of PAI in Koreans, confirmation of autoimmunity by means of laboratory testing (including 21-hydroxylase autoantibody testing) is required as soon as possible.

Excluding cases with an unknown etiology, the most common cause of PAI diagnosed before the year 2000 was adrenal tuberculosis; thereafter, adrenal tuberculosis and adrenal gland metastases were both leading causes of PAI. This means that the etiology changed dramatically as the prevalence of tuberculosis declined. Compared with the high prevalence of adrenal tuberculosis and adrenal gland metastases in adult-onset PAI, in childhood-onset PAI---which rarely presented before 10 years of age---the most common causes were congenital adrenal hypoplasia, familial glucocorticoid deficiency, and Allgrove\'s syndrome, suggesting a close association with genetic defects. These findings show that the etiology of PAI varies according to the characteristics of the study population.

In the present survey, we observed that once-daily prednisolone was the preferred pharmacological replacement regimen (69.4%) for glucocorticoid deficiency. The median dose of prednisolone administered in Korea (7.5 mg/day) is higher than that recommended by current clinical practice guidelines (3 to 5 mg/day). In most industrialized countries, hydrocortisone was reported to be the most frequently used drug as replacement. Because of its short half-life (approximately 90 minutes), if multiple dosing is employed hydrocortisone can mimic physiologic conditions; this may be beneficial in avoiding long-term complications of glucocorticoid replacement. Moreover, hydrocortisone is a more potent drug for combined mineralocorticoid deficiency than are other replacement drugs, including prednisolone. Hence, the current guideline recommends the use of hydrocortisone (15 to 25 mg/day) as first-line glucocorticoid replacement therapy for patients with PAI \[[@B1]\]. The most likely reason for the preferred use of prednisolone is the decline in adherence to hydrocortisone therapy due to the need for multiple dosing. Another hypothesis is that the relatively low mineralocorticoid deficiency rate---a result of the high salt intake of Koreans---may have averted clinically significant problems with prednisolone treatment, which has less mineralocorticoid activity than hydrocortisone \[[@B22][@B23]\]. However, in the present study, laboratory tests for plasma aldosterone concentrations and plasma renin activity were performed in only half of the patients who underwent corticotropin stimulation testing. The low level of surveillance for mineralocorticoid deficiency could have resulted in suboptimal treatment of patients with combined mineralocorticoid deficiency, in particular, of those receiving prednisolone. Furthermore, the fludrocortisone treatment rate (27.1%) was significantly lower in this study than in studies from other countries (70% to 90%) \[[@B7][@B24][@B25]\]. Therefore, we recommend active surveillance for mineralocorticoid status at diagnosis. This should ensure that patients with confirmed mineralocorticoid deficiency receive appropriate treatment with fludrocortisone and/or glucocorticoid replacement with an agent with high mineralocorticoid activity, such as hydrocortisone.

The prevalence of type 2 diabetes mellitus, hypertension, and osteoporosis increased during the follow-up period, consistent with previous reports \[[@B26][@B27]\]. This seems to be associated with glucocorticoid replacement therapy. Long-term glucocorticoid treatment can result in several complications, including metabolic diseases, deterioration in bone strength, and decreased quality of life \[[@B28][@B29][@B30]\]. Fracture and quality of life assessments were not available in the present study. Although we could not compare the prevalence of comorbidities in PAI patients and in healthy subjects, the increased prevalence of such complications during the treatment period is itself meaningful. Because patients with PAI require long-term glucocorticoid replacement therapy, these findings serve to remind clinicians that it is important to pay close attention to the occurrence of long-term complications, in addition to the treatment outcome.

In the present study, the overall mortality rate was 11.9%, with a disease-specific mortality rate of 3.1%. However, half of the registered patients were lost to follow-up; hence, the actual mortality rate may be higher than what was observed. Population-based studies reported more than a 2-fold mortality increase in patients with PAI, associated with malignancy, cardiovascular disease, and infectious conditions \[[@B31][@B32]\]. Contrary to previous studies, a recent survey in Norway showed no significant mortality increase among PAI patients. However, in a subgroup analysis, younger age (\<40 years of age) was associated with a twofold increase in the standardized mortality ratio \[[@B3]\]. One possible reason for the inconsistent mortality data is that the duration and dose of glucocorticoid replacement therapy differs according to the population studied. Nevertheless, younger age certainly seems to be associated with high mortality in terms of acute adrenal failure, infections, and sudden death \[[@B3]\].

There are several regards to be discussed in the present study. First, because this study was a registry-based multicenter survey which retrospectively collected patients\' medical records more than 15 years, there were considerable differences in methods for biochemical measurements such as cortisol and ACTH across the individual institution and even in the same institution over time. Furthermore, the diagnostic criteria for an optimal response to the corticotropin stimulation test were not consistent during the study period. There also may be some possibility that certain critical illness or drugs that could affect adrenal function were not excluded at the diagnosis. Given that limitations, we did not consider a specific cut-off cortisol value for the diagnosis of PAI, but included the diagnostic criteria of "a suboptimal response to the corticotropin stimulation test" to allow endocrinologists to clarify the diagnosis from the clinicians\' perspectives. Second, the median basal cortisol level was not that low. Considering the sensitivity of cortisol measurements, it may be attributed to the various serum cortisol measurement methods, difference in normal serum cortisol range, and when cortisol was measured during the day. In addition, we could not collect the data on the specified malignancy history and more details regarding mortality. Because cause of death was analyzed based on the answers to surveys alone, it may not fully reflect actual mortality data in our study.

Notwithstanding several limitations attributed to the retrospective nature of the present study, it is valuable as the first multicenter, nationwide survey analyzing the epidemiology of PAI in South Korea. This survey provides a comprehensive overview of the epidemiology, clinical characteristics, treatment, and mortality of patients with PAI in Korea. Notably, the cause of PAI was not identified in \>30% of patients, suggesting that efforts to clarify the exact etiology of PAI are needed. Furthermore, these data imply the need to improve the glucocorticoid and mineralocorticoid replacement strategies currently used, giving extra attention to countering the long-term complications associated with treatment. Given the low incidence of PAI in Korea, further follow-up studies of large, unbiased cohorts are needed to better understand the clinical impact of PAI.
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###### Supplemental Fig. S1

Distribution of age at diagnosis in men (orange bars) and women (gray bars) patients with primary adrenal insufficiency.

![Observed incidence of primary adrenal insufficiency in Korea over time.](enm-32-466-g001){#F1}

![Geographic distribution of patients with primary adrenal insufficiency in Korea.](enm-32-466-g002){#F2}

![Primary adrenal insufficiency etiologic pattern in patients diagnosed before 2000 and between 2000 and 2014. Tbc, tuberculosis; ALDS, adrenoleukodystrophy; PGA, polyglandular autoimmune syndrome; POEMS, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.](enm-32-466-g003){#F3}

![Prevalence of comorbidities at diagnosis and during follow-up in patients with primary adrenal insufficiency. ^a^*P*\<0.05.](enm-32-466-g004){#F4}

###### Demographic Characteristics of Patients with Primary Adrenal Insufficiency

![](enm-32-466-i001)

  Year of diagnosis      Overall patients   Before 2000   2000--2014   *P* value
  ---------------------- ------------------ ------------- ------------ -----------
  Number                 269                52            217          
  Age at diagnosis, yr   49.0±19.7          30.7±21.0     53.4±16.6    \<0.001
   \<10                  14 (5.2)           12 (23.1)     2 (0.9)      
   10--19                14 (5.2)           8 (15.4)      6 (2.8)      
   20--29                17 (6.3)           4 (7.7)       13 (6.0)     
   30--39                29 (10.8)          6 (11.5)      23 (10.6)    
   40--49                49 (18.2)          11 (21.2)     38 (17.5)    
   50--59                57 (21.2)          7 (13.5)      50 (23.0)    
   60--69                51 (19.0)          3 (5.8)       48 (22.1)    
   70--79                34 (12.6)          1 (1.9)       33 (15.2)    
   ≥80                   4 (1.5)            \-            4 (1.8)      
  Gender                                                               0.147
   Men                   169 (62.8)         32 (61.5)     137 (63.1)   
   Women                 100 (37.2)         20 (38.5)     80 (36.9)    

Values are expressed as mean±SD or number (%).

###### Glucocorticoid and Mineralocorticoid Replacement Therapy in Primary Adrenal Insufficiency Patients

![](enm-32-466-i002)

  Type of treatment               No. of patients (%)   Regimen   Median daily dose, mg   
  ------------------------------- --------------------- --------- ----------------------- -----
  Glucocorticoid replacement      245 (91.1)                                              
   Prednisolone                   170 (69.4)            q.d.      132 (77.6)              7.5
  b.i.d.                          38 (22.4)                                               
   Hydrocortisone                 65 (26.5)             q.d.      12 (18.5)               20
  b.i.d.                          50 (76.9)                                               
  t.i.d.                          3 (4.6)                                                 
   Dexamethasone                  5 (2.0)               q.d.      3 (60.0)                4
  b.i.d.                          2 (40.0)                                                
   Deflazacort                    2 (0.8)               q.d.      2 (100.0)               7.5
   Unknown                        3 (1.2)               \-        \-                      \-
  Mineralocorticoid replacement   73 (27.1)             q.d.      73 (100.0)              0.1

Values are expressed as number (%).

q.d., once daily; b.i.d., twice daily; t.i.d., 3 times daily.
